Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Arcutis Biotherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026 and furnished as Exhibit 99.1
- Investors should review Exhibit 99.1 for revenue, earnings, cash position, and guidance details
Item 5.02 · Departure/Election of Directors or Officers
- Chief Commercial Officer L. Todd Edwards departing August 21, 2026 for external opportunity, without reported disagreement
- Robert Lisicki appointed interim executive vice president August 17 and interim chief commercial officer August 21
- Lisicki receives $555,000 base salary, 50% target bonus, 145,000 stock options, and 55,000 restricted stock units
- Change-in-control protections include up to 18 months’ salary, 1.5x target bonus, COBRA reimbursement, and accelerated equity vesting
- Edwards eligible for transition payments totaling up to $175,000 through March 31, 2027ાન્ય
Item EX-99.1 · Exhibit EX-99.1
- Q2 product revenue $129.9M, up 59% YoY and 23% sequentially, confirming accelerating ZORYVE demand
- 2026 sales guidance raised to $525M–$540M from $480M–$495M, signaling stronger commercial momentum
- Net income $15.0M versus $15.9M loss in Q2 2025, with $12.6M operating cash flow supporting funding flexibility
- ZORYVE cream approved for plaque psoriasis in children aged 2+, while infant atopic dermatitis review targets February 23, 2027
- Pipeline catalysts include Q4 2026 vitiligo topline results and potential advancement decision for ZORYVE foam 0.3%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcutis Biotherapeutics, Inc. 8-K filings
Get the next ARQT 8-K as it lands
Follow ARQT for push alerts, or ask the research agent what this filing means.